DAS28 remission and clinical efficacy in rheumatoid arthritis patients with inadequate responses to methotrexate treated with abatacept: The Phase III AIM trial and a Phase IIB trial long-term extension

被引：0
|
作者：
Westhovens, R
Kremer, J
Shergy, W
Abud-Mendoza, C
Aranda, R
Becker, JC
Zhou, Y
Mokliatchouk, O
Dougados, M
机构：
[1] Univ Hosp Gasthuisberg, Louvain, Belgium
[2] Ctr Rheumatol, Albany, NY USA
[3] Albany Med Coll, Albany, NY 12208 USA
[4] Rheumatol Assoc N Alabama, Huntsville, AL USA
[5] Hosp Cent Ignac Morones Prieto, San Luis Potosi, Mexico
[6] Bristol Myers Squibb Co, Princeton, NJ USA
[7] Hosp Cochin, Paris, France
来源：
ARTHRITIS AND RHEUMATISM | 2005年 / 52卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S142 / S142
页数：1
相关论文
共 50 条
  • [1] Rapid and significant improvements in the components of the ACR criteria in abatacept-treated rheumatoid arthritis patients in the phase III aim (abatacept in inadequate responders to methotrexate) trial
    Steinfeld, S
    Moreland, L
    Abud, C
    Szechinski, J
    Ge, Z
    Aranda, R
    Becker, J
    Kremer, J
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 457 - 457
  • [2] In abatacept-treated rheumatoid arthritis patients, rapid and significant improvements were observed in the components of the ACR criteria for the phase III aim (abatacept in inadequate responders to methotrexate) trial
    Abud-Mendoza, C
    Steinfeld, S
    Aranda, R
    Becker, JC
    Kremer, J
    Thorne, C
    Teng, J
    JOURNAL OF RHEUMATOLOGY, 2006, 33 (02) : 392 - 392
  • [3] ABATACEPT CONFERS CLINICAL EFFICACY REGARDLESS OF BASELINE CRP STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO METHOTREXATE IN THE AIM TRIAL
    Sibilia, Jean
    Flipo, Rene Marc
    Combe, Bernard
    Gaillez, Corine
    Le Bars, Manuela
    Poncet, Coralie
    Elegbe, Ayanbola
    Westhovens, Rene
    RHEUMATOLOGY, 2012, 51 : 124 - 125
  • [4] Long-term efficacy of abatacept through 2 years of treatment in rheumatoid arthritis patients in the aim trial
    Kremer, J.
    Russell, A.
    Westhovens, R.
    JOURNAL OF RHEUMATOLOGY, 2007, 34 (07) : 1630 - 1630
  • [5] Safety and efficacy of abatacept over 4 years of treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate in the AIM trial
    Kremer, J. M.
    Russell, A. S.
    Emery, P.
    Abud-Mendoza, C.
    Szechinski, J.
    Zhao, C.
    Becker, J-C
    Westhovens, R.
    ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S308 - S309
  • [6] Safety and Efficacy of Abatacept Over 4 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate in the AIM Trial
    Russell, A. S.
    Kremer, J. M.
    Emery, P.
    Abud-Mendoza, C.
    Szechinski, J.
    Zhao, C.
    Becker, J-C
    Westhovens, R.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2608 - 2609
  • [7] Efficacy and safety of the selective co-stimulation modulator abatacept with methotrexate for treating rheumatoid arthritis: 1-year clinical and radiographic results from the Phase III AIM (Abatacept in Inadequate responders to Methotrexate) trial
    Hall, S.
    Hanrahan, P.
    Cheng, T. T.
    Lin, H. Y.
    Westhovens, R.
    Moreland, L.
    Emery, P.
    Russell, A.
    Kremer, J.
    INFLAMMATION RESEARCH, 2005, 54 : S110 - S110
  • [8] Long-term efficacy of abatacept through 2 years of treatment in rheumatoid arthritis patients in the AIM trial.
    Kremer, J.
    Westhovens, R.
    Russell, A.
    Emery, P.
    Aranda, R.
    Becker, J-C
    Teng, J.
    Schmidely, N.
    Le Bars, M.
    Moreland, L.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S247 - S247
  • [9] Long-term efficacy and safety of abatacept through 3 years of treatment in rheumatoid arthritis patients in the aim trial
    van Vollenhoven, Ronald
    Kremer, J.
    Westhovens, R.
    Luggen, M.
    Russell, A.
    Aranda, R.
    Becker, J-C
    Joshi, C.
    Gandhi, M.
    Genovese, M. C.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 51 - 51
  • [10] Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
    Kremer, Joel M.
    Russell, Anthony S.
    Emery, Paul
    Abud-Mendoza, Carlos
    Szechinski, Jacek
    Westhovens, Rene
    Li, Tracy
    Zhou, Xianhuang
    Becker, Jean-Claude
    Aranda, Richard
    Peterfy, Charles
    Genant, Harry K.
    ANNALS OF THE RHEUMATIC DISEASES, 2011, 70 (10) : 1826 - 1830
12345